Compare OGI & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OGI | CBIO |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.8M | 252.6M |
| IPO Year | N/A | N/A |
| Metric | OGI | CBIO |
|---|---|---|
| Price | $1.65 | $13.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $25.60 |
| AVG Volume (30 Days) | ★ 525.2K | 182.3K |
| Earning Date | 12-16-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $164,107,753.00 | N/A |
| Revenue This Year | $59.31 | N/A |
| Revenue Next Year | $15.12 | N/A |
| P/E Ratio | $38.60 | ★ N/A |
| Revenue Growth | ★ 50.01 | N/A |
| 52 Week Low | $0.85 | $9.81 |
| 52 Week High | $2.08 | $21.40 |
| Indicator | OGI | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.83 | 47.55 |
| Support Level | $1.45 | $12.59 |
| Resistance Level | $1.72 | $16.35 |
| Average True Range (ATR) | 0.08 | 1.08 |
| MACD | 0.02 | -0.10 |
| Stochastic Oscillator | 70.37 | 18.99 |
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.